Dr Reddys Laboratories (RDY) Other Non-Current Liabilities (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Other Non-Current Liabilities for 10 consecutive years, with $37.0 million the latest figure, recorded in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 5.13% year-over-year to $37.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.0 million (down 5.13% YoY) and the FY2026 annual result came in at $37.0 million, down 5.13% from the prior year.
• Other Non-Current Liabilities fell to $37.0 million in Q1 2026 per RDY's latest filing, from $39.0 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for RDY reached as high as $48.0 million in Q1 2024 and fell as low as $32.0 million in Q1 2022.
• A 5-year average of $38.2 million and a median of $37.0 million in 2026 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities soared 37.14% — and 2025, when it dropped 18.75%.
• Year by year, Other Non-Current Liabilities stood at $32.0 million in 2022, then advanced by 9.38% to $35.0 million in 2023, then surged by 37.14% to $48.0 million in 2024, then slipped by 18.75% to $39.0 million in 2025, then retreated by 5.13% to $37.0 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $37.0 million, $39.0 million, and $48.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.